Cinnamaldehyde/ chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer

Molecular Medicine Reports

Volumn 9, Issue 2, 2014, Pages 669-676

  Yu, Chen ^a   Liu, Shen Lin ^b   Qi, Ming Hao ^b   Zou, Xi ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chemotherapeutic agents; Cinnamaldehyde; Colorectal cancer; Drug metabolizing genes; Synergistic interaction

Indexed keywords

ACROLEIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CINNAMOMUM AROMATICUM; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDONUCLEASES; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; METABOLIC DETOXICATION, DRUG; ORGANOPLATINUM COMPOUNDS; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

EID: 84893877683     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1830     Document Type: Article

References (55)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000.
7. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
10. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
11. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, et al: Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 16: 3133-3143, 2010.
12. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009.
13. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al: Disease-free survival versus overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23: 8664-8670, 2005.
14. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, et al: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12: 38-50, 2007.
15. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326-5334, 2008.
16. Carnaghi C, Zucali P and Garassino I: Combination of 5-Fluorouracil and folinic acid-is it still the standard therapy for advanced colorectal carcinoma? Tumori 86: S19-S25, 2000.
17. Garg AK, Buchholz TA and Aggarwal BB: Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 7: 1630-1647, 2005.
18. Ahn DK (ed): Illustrated Book of Korean Medicinal Herbs. Kyohak Publishing Co. Ltd., Seoul, Republic of Korea, pp562-563, 1998.
19. Koh WS, Yoon SY, Kwon BM, Jeong TC, Nam KS and Han MY: Cinnamaldehyde inhibits lymphocyte proliferation and modulates T-cell differentiation. Int J Immunopharmacol 20: 643-660, 1998.
20. Bullerman LB, Lieu FY and Seier SA: Inhibition of growth and aflatoxin production by cinnamon and clove oils, cinnamic aldehyde and eugenol, J Food Sci 42: 1107-1109, 1977.
21. Kwon BM, Lee SH, Choi SU, Park SH, Lee CO, Cho YK, et al: Synthesis and in vitro cytotoxicity of cinnamaldehydes to human solid tumor cells. Arch Pharm Res 21: 147-152, 1998.
22. Shaughnessy DT, Setzer RW and DeMarini DM: The antimutagenic effect of vanillin and cinnamaldehyde on spontaneous mutation in Salmonella TA104 is due to a reduction in mutations at GC but not AT sites. Mutat Res 480-481: 55-69, 2001.
23. Kwon BM, Lee SH, Cho YK, Bok SH, So SH, Youn MR, et al: Synthesis and biological activity of cinnamaldehydes as angiogenesis inhibitors. Bioorg Med Chem Lett 7: 2473-2476, 1997.
24. Lee CW, Hong DH, Han SB, Park SH, Kim HK and Kwon BM: Inhibition of human tumor growth by 2'-hydroxy-and 2'-benzoyloxycinnamaldehydes. Planta Med 65: 263-266, 1999.
25. Kwon BM, Cho YK, Lee SH, Nam JY, Bok SH, Chun SK, Kim JA and Lee IR: 2'-Hydroxycinnamaldehyde from stem bark of Cinnamomum cassia. Planta Med 62: 183-184, 1996.
26. Huang TC, Fu HY, Ho CT, Tan D, Huang YT and Pan MH: Induction of apoptosis by cinnamaldehyde from indigenous cinnamon Cinnamomum osmophloeum Kaneh through reactive oxygen species production, glutathione depletion, and caspase activation in human leukemia K562 cells. Food Chem 103: 434-443, 2007.
27. Ka H, Park HJ, Jung HJ, Choi JW, Cho KS, Ha J, et al: Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett 196: 143-152, 2003.
28. Wu SJ, Ng LT and Lin CC: Effects of vitamin E on the cinnamaldehyde- induced apoptotic mechanism in human PLC/PRF/5 cells. Clin Exp Pharmacol Physiol 31: 770-776, 2004.
29. Chew EH, Nagle AA, Zhang Y, Scarmagnani S, Palaniappan P, Bradshaw TD, et al: Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med 48: 98-111, 2010.
30. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
31. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
32. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
33. Barret JM, Etiévant C and Hill BT: In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45: 471-476, 2000.
34. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K and Adachi KI: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 42: 91-98, 1998.
35. Perez EA and Buckwalter CA: Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol 41: 448-452, 1998.
36. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
37. Aschele C, Lonardi S and Monfardini S: Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28: 27-47, 2002.
38. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
39. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
40. Grem JL, Danenberg KD, Behan K, Parr A, Young L, Danenberg PV, et al: Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National cancer Institute's Anticancer Drug Screen. Clin Cancer Res 7: 999-1009, 2001.
41. Nita ME, Tominaga O, Nagawa H, Tsuruo T and Muto T: Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 45: 2117-2122, 1998.
42. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004.
43. Su F, Overholtzer M, Besser D and Levine AJ: WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev 16: 46-57, 2002.
44. Tian C, Zhou ZG, Meng WJ, Sun XF, Yu YY, Li L, et al: Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J Gastroenterol 13: 3878-3882, 2007.
45. Hashimoto Y, Shindo-Okada N, Tani M, Nagamachi Y, Takeuchi K, et al: Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses in vivo tumor growth and metastasis of K-1735 murine melanoma cells. J Exp Med 187: 289-296, 1998.
46. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003.
47. Motamed-Khorasani A, Jurisica I, Letarte M, Shaw PA, Parkes RK, Zhang X, et al: Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 26: 198-214, 2007.
48. Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, et al: Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 3: 763-780, 2002.
49. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.
50. Khanna KK and Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254, 2001.
51. Rudolf E, Rudolf K and Cervinka M: Camptothecin induces p53-dependent and-independent apoptogenic signaling in melanoma cells. Apoptosis 16: 1165-1176, 2011.
52. Kaye SB: New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 78 (Suppl 3): 1-7, 1998.
53. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
54. Wu SJ, Ng LT and Lin CC: Cinnamaldehyde-induced apoptosis in human PLC/PRF/5 cells through activation of the proapoptotic Bcl-2 family proteins and MAPK pathway. Life Sci 77: 938-951, 2005.
55. Kwon HK, Hwang JS, So JS, Lee CG, Sahoo A, Ryu JH, et al: Cinnamon extract induces tumor cell death through inhibition of NFkappaB and AP1. BMC Cancer 10: 392, 2010.